ES2091173T1 - Nueva composicion farmaceutica que contiene el inhibidor de ace ramipril y un compuesto de dihidropiridina. - Google Patents

Nueva composicion farmaceutica que contiene el inhibidor de ace ramipril y un compuesto de dihidropiridina.

Info

Publication number
ES2091173T1
ES2091173T1 ES95930771T ES95930771T ES2091173T1 ES 2091173 T1 ES2091173 T1 ES 2091173T1 ES 95930771 T ES95930771 T ES 95930771T ES 95930771 T ES95930771 T ES 95930771T ES 2091173 T1 ES2091173 T1 ES 2091173T1
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
ramipril
dihydropyridine
ace
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES95930771T
Other languages
English (en)
Other versions
ES2091173T3 (es
Inventor
Brigitte Bauer
Christer Karlsson
Per Johan Lundberg
Berit Nilsson
Anders Sandberg
Alfred Sickmuller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9402925A external-priority patent/SE9402925D0/xx
Priority claimed from SE9402924A external-priority patent/SE9402924D0/xx
Application filed by Astra AB filed Critical Astra AB
Publication of ES2091173T1 publication Critical patent/ES2091173T1/es
Application granted granted Critical
Publication of ES2091173T3 publication Critical patent/ES2091173T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE PRESENTA UNA COMPOSICION FARMACEUTICA QUE ES UNA COMBINACION DEL RAMIPRIL QUE ES UN INHIBIDOR DEL ACE Y UN ANTAGONISTA DEL CALCIO DE UNO DE LOS COMPUESTOS DE TIPO DIHIDROPIRIDINA, FELODIPINA, NITRENDIPINA, NIFEDIPINA Y LACIDIPINA. LA COMPOSICION FARMACEUTICA SE UTILIZA PARA LA TERAPIA Y EL TRATAMIENTO DE LA HIPERTENSION.
ES95930771T 1994-09-02 1995-08-30 Nueva composicion farmaceutica que contiene el inhibidor de la ace ramipril y un compuesto de dehidropiridina. Expired - Lifetime ES2091173T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402925A SE9402925D0 (sv) 1994-09-02 1994-09-02 Novel oral pharmaceutical composition
SE9402924A SE9402924D0 (sv) 1994-09-02 1994-09-02 Novel pharmaceutical composition

Publications (2)

Publication Number Publication Date
ES2091173T1 true ES2091173T1 (es) 1996-11-01
ES2091173T3 ES2091173T3 (es) 2002-12-01

Family

ID=26662130

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95930771T Expired - Lifetime ES2091173T3 (es) 1994-09-02 1995-08-30 Nueva composicion farmaceutica que contiene el inhibidor de la ace ramipril y un compuesto de dehidropiridina.

Country Status (32)

Country Link
US (1) US6086919A (es)
EP (1) EP0726766B1 (es)
JP (1) JP3776931B2 (es)
KR (1) KR100438133B1 (es)
CN (1) CN1134665A (es)
AT (1) ATE217187T1 (es)
AU (1) AU695865B2 (es)
CA (1) CA2174338C (es)
CZ (1) CZ292224B6 (es)
DE (2) DE726766T1 (es)
DK (1) DK0726766T3 (es)
EE (1) EE03550B1 (es)
EG (1) EG24435A (es)
ES (1) ES2091173T3 (es)
FI (1) FI117616B (es)
GR (1) GR960300055T1 (es)
HU (1) HU226894B1 (es)
IL (1) IL115059A (es)
IS (1) IS1781B (es)
MX (1) MX9601586A (es)
MY (1) MY119489A (es)
NO (1) NO308694B1 (es)
NZ (2) NZ292298A (es)
PL (1) PL186745B1 (es)
PT (1) PT726766E (es)
RU (1) RU2184563C2 (es)
SA (1) SA95160287B1 (es)
SI (1) SI0726766T1 (es)
SK (1) SK283633B6 (es)
TR (1) TR199501077A2 (es)
TW (1) TW483763B (es)
WO (1) WO1996007400A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19715594A1 (de) 1997-04-15 1998-10-22 Bayer Ag Analgetika-Kombination
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
KR100356374B1 (ko) * 2000-09-14 2002-10-19 사회복지법인삼성생명공익재단(삼성서울병원) 안지오텐신 전환효소 억제제의 부작용으로 발생하는마른기침을 저해하기 위한 철분을 포함하는 기침 저해조성물
CA2357982A1 (en) * 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
US20050202081A1 (en) * 2002-01-15 2005-09-15 Deepak Bahl Stable pharmaceutical compositions comprising ace inhibitor(s)
USD481456S1 (en) 2002-01-30 2003-10-28 Smithkline Beecham P.L.C. Capsule
US6844361B2 (en) * 2002-02-04 2005-01-18 Aventis Pharma Deutschland Gmbh Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
US20030175342A1 (en) * 2002-03-14 2003-09-18 Karl Kolter Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
US20050101640A1 (en) * 2002-10-16 2005-05-12 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
ES2311117T3 (es) * 2002-12-10 2009-02-01 Novartis Ag Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa.
GB0301471D0 (en) * 2003-01-22 2003-02-19 Biochemie Gmbh Organic compounds
ES2322854T3 (es) * 2003-06-26 2009-06-30 Teva Pharmaceutical Industries Limited Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico.
MXPA06003320A (es) * 2003-09-24 2006-06-08 Combinatorx Inc Regimenes terapeuticos para administrar combinaciones de farmacos.
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
US7329418B2 (en) * 2004-05-21 2008-02-12 Accu Break Technologies, Inc. Pharmaceutical tablets having height greater than width
US7780985B2 (en) * 2005-07-12 2010-08-24 Accu-Break Technologies, Inc. Tablets having a printed separation mark to guide breaking
US7838031B2 (en) 2004-05-21 2010-11-23 Lawrence Solomon Method of administering a partial dose using a segmented pharmaceutical tablet
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
US7318935B2 (en) * 2004-05-21 2008-01-15 Accu-Break Technologies, Inc. Pharmaceutical tablets with active and inactive segments
US7713547B2 (en) 2004-05-21 2010-05-11 Accu-Break Pharmaceuticals, Inc. Method of administering a partial dose of a segmented pharmaceutical tablet
ES2385832T3 (es) * 2004-05-21 2012-08-01 Accu-Break Technologies, Inc. Comprimidos farmacéuticos que presentan un segmento relativamente inactivo
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
KR100593795B1 (ko) 2004-10-12 2006-06-30 대원제약주식회사 안정성이 개선된 라미프릴을 포함하는 경구투여용 제제
KR20070085754A (ko) * 2004-11-05 2007-08-27 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정화된 라미프릴 조성물 및 제조 방법
KR100714616B1 (ko) * 2005-06-23 2007-05-07 삼성전기주식회사 지수 함수 발생기 및 이를 이용한 가변 이득 증폭기
EA200800451A1 (ru) * 2005-07-28 2008-08-29 Релайэнт Фармасьютикалз, Инк. Лечение дигидропиридиновыми блокаторами кальциевых каналов и жирными кислотами омега-3 и их комбинированным продуктом
CA2628955A1 (en) * 2005-11-07 2007-05-18 Edward S. Wilson Compositions of stabilized ramipril in combination with another active agent
US8231902B2 (en) * 2005-11-18 2012-07-31 Accu-Break Technologies, Inc. Segmented pharmaceutical dosage forms
US20070237815A1 (en) * 2006-04-06 2007-10-11 Lawrence Solomon Dosage forms and methods comprising amlodipine and chlorthalidone
US20080015188A1 (en) * 2006-04-19 2008-01-17 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
WO2008021875A2 (en) * 2006-08-08 2008-02-21 Accu-Break Technologies, Inc. Pharmaceutical tablets containing a plurality of active segments
WO2008067485A1 (en) * 2006-11-30 2008-06-05 Accu-Break Technologies, Inc. Divisible osmotic dosage forms and methods of use
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
SI2178513T1 (sl) * 2007-06-22 2011-05-31 Bristol Myers Squibb Co Tabletni sestavki vsebujoäśi atazanavir
ES2360336T3 (es) * 2007-06-22 2011-06-03 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
EP2178512B1 (en) * 2007-06-22 2011-03-09 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
DK2170292T3 (da) * 2007-06-22 2014-04-07 Bristol Myers Squibb Holdings Ireland Atazanavirholdige sammensætninger i tabletform
US20110027356A1 (en) * 2008-01-25 2011-02-03 Duo-Ge Combination of Oral Medicaments Bonded by a Wrapping
EP2309985B1 (en) 2008-07-28 2018-03-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
SI23149A (sl) 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
CN101843892B (zh) * 2010-05-18 2013-03-06 广州白云山制药股份有限公司广州白云山制药总厂 包括依那普利速释部分和非洛地平缓释部分的药物组合物制剂
CA2955425A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
SE429652B (sv) * 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3437917A1 (de) * 1984-10-17 1986-04-17 Bayer Ag, 5090 Leverkusen Kombination von dihydropyridinen mit ace-hemmern sowie ihre verwendung in arzneimitteln
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
DE3704661A1 (de) * 1987-02-14 1988-08-25 Hoechst Ag Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
TW197945B (es) * 1990-11-27 1993-01-11 Hoechst Ag
DE4109134A1 (de) * 1991-03-20 1992-09-24 Knoll Ag Erzeugnisse, enthaltend verapamil und trandolapril
CA2070085A1 (en) * 1991-05-31 1992-12-01 Gerald P. Polli Ace inhibitor and calcium channel blocker for use in treating hypertension
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
JPH11500140A (ja) * 1995-03-16 1999-01-06 ファイザー・インコーポレーテッド アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物

Also Published As

Publication number Publication date
RU2184563C2 (ru) 2002-07-10
WO1996007400A1 (en) 1996-03-14
SK283633B6 (sk) 2003-11-04
EG24435A (en) 2009-06-25
EE03550B1 (et) 2001-12-17
SK55896A3 (en) 1997-03-05
EE9600072A (et) 1996-12-16
FI961863A0 (fi) 1996-05-02
AU695865B2 (en) 1998-08-27
DK0726766T3 (da) 2002-07-22
US6086919A (en) 2000-07-11
NO961726L (no) 1996-04-29
IL115059A (en) 2003-10-31
CA2174338A1 (en) 1996-03-14
PL186745B1 (pl) 2004-02-27
IS1781B (is) 2001-10-01
EP0726766B1 (en) 2002-05-08
ATE217187T1 (de) 2002-05-15
SA95160287B1 (ar) 2006-05-28
DE69526640T2 (de) 2002-11-07
PL314084A1 (en) 1996-08-19
MY119489A (en) 2005-06-30
PT726766E (pt) 2002-10-31
FI961863L (fi) 1996-05-02
EP0726766A1 (en) 1996-08-21
HU9601146D0 (en) 1996-07-29
FI117616B (fi) 2006-12-29
SA95160287A (ar) 2005-12-03
CA2174338C (en) 2009-11-03
ES2091173T3 (es) 2002-12-01
DE726766T1 (de) 1997-01-30
SI0726766T1 (en) 2002-10-31
CZ117396A3 (en) 1996-09-11
AU3402995A (en) 1996-03-27
JP3776931B2 (ja) 2006-05-24
HU226894B1 (en) 2010-01-28
GR960300055T1 (en) 1996-10-31
IL115059A0 (en) 1996-01-19
CN1134665A (zh) 1996-10-30
IS4337A (is) 1996-04-18
NZ292298A (en) 1998-02-26
JPH09504806A (ja) 1997-05-13
TR199501077A2 (tr) 1996-06-21
NO308694B1 (no) 2000-10-16
CZ292224B6 (cs) 2003-08-13
HK1001811A1 (en) 1998-07-10
KR100438133B1 (ko) 2004-09-04
TW483763B (en) 2002-04-21
NO961726D0 (no) 1996-04-29
MX9601586A (es) 1998-01-31
DE69526640D1 (de) 2002-06-13
NZ329556A (en) 2000-07-28
HUT76049A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
ES2091173T1 (es) Nueva composicion farmaceutica que contiene el inhibidor de ace ramipril y un compuesto de dihidropiridina.
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
NO307417B1 (no) Ikke-peptidylintegrininhibitorer med spesifisitet for GPIIbIIIa-reseptoren, farmasøytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene til fremstilling av medikamenter
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
AR034691A1 (es) Composiciones farmaceuticas de administracion oral, que contiene un inhibidor de lipasa gastrointestinal, el comprimido masticable y la galleta que los comprende
DE69827821D1 (de) Synergistisch,analgetische zusammensetzung mit opiod-analgetika und zyklooxygenase-2 inhibitoren
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
MX9706957A (es) Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
BR0213181A (pt) Combinações de inibidor de cox-2
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
MX9805506A (es) Uso medico novedoso de un inhibidor de la dispepsia relacionada con acido para el tratamiento de sintomas dispepticos.
ES2164168T3 (es) Antagonistas de receptores de fibrinogeno que tienen residuos de beta-aminoacido sustituidos y composiciones farmaceuticas que comprenden los mismos.
UY26329A1 (es) Antagonistas de los receptores de vitronectina
ES2182524T3 (es) Composiciones de hidroxiomeprazol y sus utilizaciones.
ECSP993102A (es) Composiciones farmaceuticas
ECSP993090A (es) Composicion farmaceutica de proteinas erizo y su uso
MX9205204A (es) Composicion farmaceutica que comprende compuestos antagonistas del receptor 5-hidroxitriptamina
ES2188797T3 (es) Sales de n-(4-oxo-2-(1h-tetrazoil-5-il)-4h-1 benzopran-8-il)-4-(4-fenilbutoxi)benzamida.
ECSP972074A (es) Composiciones farmaceuticas para el tratamiento de rinitis
AR034045A1 (es) Empleo de heterociclos biciclicos para el tratamiento y prevencion de enfermedades tromboticas arteriales
ECSP972279A (es) Antagonistas del receptor de vitronectina
ECSP993242A (es) Antagonistas del receptor de vitronectina v